In the context of APL, it has now become imperative to explore whether leukemic cells driven by the same oncogenic driver, PML/RARα, exhibit diverse cellular states; if so, to what extent the cellular composition and transcriptional heterogeneity might impact the outcomes of targeted therapy in APL. This evidence concerns the gene PML and acute promyelocytic leukemia.